Todd Bauer, MD
Hematology & Oncology · Nashville, TNNPI 1336296136
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 57 manufacturers reported payments, led by Pfizer at 39.5% of the total. Reporting peaked in 2021 at $85,022 and has fallen 69.2% since, to $26,207 in 2025. Among hematology & oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $799.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$141K
- Bayer$99K
- Lilly USA, LLC$69K
- Whitehall International Inc$8K
- E.r. Squibb & Sons, L.L.C.$7K
- Eli Lilly$5K
- plus $29K from 51 others
Across 3,027 payments — averaging $3500.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4M
- Incyte Corporation$1.1M
- Novartis$1M
- E.r. Squibb & Sons, L.L.C.$864K
- AbbVie$622K
- Pfizer$597K
- plus $2.4M from 18 others
What the payments were for
- Consulting fees$138,40039%
- Speaking & faculty fees$198,79856%
- Travel & lodging$10,6863%
- Food & beverage$9,1593%
- Education$1950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LORBRENA$139,129
- Vitrakvi$98,058
- RETEVMO$10,800
- BRAFTOVI$9,013
- MEKTOVI$8,283
- VIZIMPRO$8,180
- OPDIVO$4,770
- FOUNDATIONACT$4,432
- FOUNDATIONFOCUS$4,432
- FOUNDATIONONE CDX$4,432
- FOUNDATIONONE HEME$4,432
- FOUNDATIONONE$4,432
- XALKORI$3,700
- LIBTAYO$2,673
- Non-Covered Product$2,130
- Venclexta$250
- EPKINLY$250
- UKONIQ$249
- Orserdu$205
- Yescarta$147
How this compares
$357,238 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 62 | $914,104 |
| ImbruvicaIbrutinib | 31 | $538,121 |
| VerzenioAbemaciclib | 21 | $322,577 |
| JakafiRuxolitinib Phosphate | 20 | $280,502 |
| LorbrenaLorlatinib | 14 | $268,488 |
| CalquenceAcalabrutinib Maleate | 20 | $247,334 |
| NubeqaDarolutamide | 13 | $176,736 |
| BrukinsaZanubrutinib | 11 | $146,568 |
| Abiraterone Acetate | 47 | $137,079 |
| KisqaliRibociclib Succinate | 11 | $123,394 |
| OrgovyxRelugolix | 40 | $99,208 |
| EliquisApixaban | 63 | $42,207 |
| XareltoRivaroxaban | 29 | $29,583 |
| Imatinib Mesylate | 14 | $21,639 |
| AranespDarbepoetin Alfa In Polysorbat | 11 | $18,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,506 | $914,10462 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $78 | $538,12131 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $69,038 | $322,82739 claims |
| PfizerLorbrena, Eliquis | $141,057 | $310,69577 claims |
| Incyte CorporationJakafi | $1,134 | $280,50220 claims |
| AstraZenecaCalquence | $4,680 | $247,33420 claims |
| BayerNubeqa | $98,524 | $176,73613 claims |
| Beigene USA, Inc.Brukinsa | $34 | $146,56811 claims |
| NovartisKisqali | $253 | $123,39411 claims |
| Johnson & JohnsonXarelto | $169 | $29,58329 claims |
| AmgenAranesp | $103 | $18,19511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
- Jack ErterNashville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.